Jefferies Maintains a 'Buy' on Amarin (AMRN); Concern Over NCE Delay And Meta-analysis Presents A Buying Opportunity

Article Related Articles (7) Related SEC Filings (1) Stock Quotes (1) Comments (0)

Jefferies maintains a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $28.00.

Analyst, Thomas Wei, said, "We believe investor speculation over further delays in Vascepa’s New Chemical Entity (NCE) decision, plus a minor concern for a new meta-analysis, has contributed to stock weakness. We believe the stock reaction creates an attractive entry point, as we do not believe NCE status is essential for a pharma deal given the patent prospects or that the analysis of 1-2 gram Lovaza studies predicts the outcome of Vascepa’s REDUCE-IT trial."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $13.56 yesterday, with a 52 week range of $5.99-$15.96.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Janney Capital Trims Numbers on Buckle (BKE), Margins Peaking
• UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
• UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?